Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

Scientists are learning how cancer cells outwit cutting-edge cancer therapies like checkpoint inhibitors—and developing ...

The finance round was led by OrbiMed and comes almost exactly two years after Mereo decided to pull a US IPO, blaming challenging market conditions. In the phase 1b combination study, a total of ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at ...

Domvanalimab (dom). The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that is undergoing evaluation in three registrational trials for the treatment of ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...

Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing ...